Quarterly report [Sections 13 or 15(d)]

Stock-Based Compensation (Tables)

v3.26.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation

Compensation costs that have been included in our condensed consolidated statements of operations for all stock-based compensation arrangements is set forth below:

 

 

 

Three months ended March 31,

 

(in thousands)

 

2026

 

 

2025

 

Cost of revenue

 

 

17

 

 

 

15

 

Sales and marketing

 

 

9

 

 

 

8

 

General and administrative

 

 

78

 

 

 

67

 

Research and development

 

 

8

 

 

 

(4

)

Total stock-based compensation

 

$

112

 

 

$

86

 

Schedule of Restricted Stock Unit Activity

A summary of our restricted stock unit activity for the three months ended March 31, 2026 is set forth below:

 

 

 

Shares

 

 

Weighted
Average Grant
Date Fair Value

 

Outstanding as of December 31, 2025

 

 

17,732

 

 

$

21.17

 

Granted

 

 

9,526

 

 

 

1.76

 

Released

 

 

(5,306

)

 

 

15.61

 

Forfeited

 

 

-

 

 

 

-

 

Outstanding as of March 31, 2026

 

 

21,952

 

 

$

14.09

 

Schedule of Stock Option Activity

A summary of our stock option activity under the 2018 Equity Incentive Plan (the “2018 Plan) and related information is as follows:

 

 

 

Number of
Shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Term (years)

 

Aggregate
Intrinsic
Value

 

Outstanding as of December 31, 2025

 

 

1,000

 

 

$

85.00

 

 

 

 

 

 

Granted

 

 

-

 

 

 

-

 

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

Forfeited

 

 

-

 

 

$

-

 

 

 

 

 

 

Outstanding as of March 31, 2026

 

 

1,000

 

 

$

85.00

 

 

6.36

 

$

-

 

Exercisable as of March 31, 2026

 

 

1,000

 

 

$

85.00

 

 

6.36

 

$

-

 

 

A summary of our option activity under our 2009 Equity Incentive Plan (the “2009 Plan”) and related information is as follows:

 

 

 

Number of
Shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Term (years)

 

 

Aggregate
Intrinsic
Value

 

Outstanding as of December 31, 2025

 

 

883

 

 

$

113.56

 

 

 

 

 

 

 

Granted

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Forfeited

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Outstanding as of March 31, 2026

 

 

883

 

 

$

113.56

 

 

 

2.00

 

 

$

-

 

Exercisable as of March 31, 2026

 

 

883

 

 

$

113.56

 

 

 

2.00

 

 

$

-